amino acids; magnesium chloride; potassium acetate; potassium chloride; sodium acetate
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
VEINAMINE 8% is an injectable parenteral nutrition formulation containing amino acids, electrolytes (magnesium chloride, potassium acetate, potassium chloride, sodium acetate) designed to support protein synthesis and electrolyte balance in hospitalized or nutritionally compromised patients. It is administered intravenously as part of total parenteral nutrition (TPN) regimens.
As a legacy parenteral nutrition product approaching LOE, commercial teams are likely consolidating focus to higher-margin specialty products or newer formulations.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on VEINAMINE 8% offers career stability within a mature, mission-critical hospital product category, but limited growth trajectory as LOE approaches. Roles are increasingly focused on operational excellence, cost management, and defending market share rather than innovation or expansion.
Worked on VEINAMINE 8% at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo